OOIR: Observatory of International Research

Papers

(The TQCC of Nature Medicine is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Post-acute COVID-19 syndrome	3367
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection	3283
Attributes and predictors of long COVID	1738
Long-term cardiovascular outcomes of COVID-19	1284
AI in health and medicine	1057
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection	898
Large language models in medicine	852
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma	840
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies	802
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries	736
Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries	674
Symptoms and risk factors for long COVID in non-hospitalized adults	614
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies	595
Targeting metastatic cancer	579
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals	576
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies	570
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination	561
Long COVID after breakthrough SARS-CoV-2 infection	560
Biomarkers for neurodegenerative diseases	553
SARS-CoV-2 infection of the oral cavity and saliva	552
Single-cell multi-omics analysis of the immune response in COVID-19	527
Toward personalized treatment approaches for non-small-cell lung cancer	524
Immune determinants of COVID-19 disease presentation and severity	502
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2	501
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study	500

Deep learning in histopathology: the path to the clinic	493
Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus	483
Intratumoral heterogeneity in cancer progression and response to immunotherapy	479
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial	477
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa	473
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial	470
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera	469
Long COVID in a prospective cohort of home-isolated patients	464
Looking beyond COVID-19 vaccine phase 3 trials	463
Understanding COVID-19 vaccine hesitancy	461
Cellular senescence and senolytics: the path to the clinic	456
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer	445
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection	444
Four distinct trajectories of tau deposition identified in Alzheimer’s disease	438
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus	437
Partial recovery of visual function in a blind patient after optogenetic therapy	413
Brown adipose tissue is associated with cardiometabolic health	412
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK	403
Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids	399
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial	398
Multimodal biomedical AI	394
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy	393
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine	389
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer	383
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial	381
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants	379
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial	375
Federated learning for predicting clinical outcomes in patients with COVID-19	361
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis	354
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant	348
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial	347
Acute and postacute sequelae associated with SARS-CoV-2 reinfection	346
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar	343
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination	342
Unexplained post-acute infection syndromes	337
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar	336
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination	332
Long-term neurologic outcomes of COVID-19	325
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults	324
Sixteen novel lineages of SARS-CoV-2 in South Africa	323
Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations	321
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination	316
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma	313
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer	312
SARS-CoV-2 variants of concern are emerging in India	308
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant	306
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster	298
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England	297
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells	295
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results	292

COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence	286
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial	284
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures	283
Closed-loop neuromodulation in an individual with treatment-resistant depression	282
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination	280
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection	277
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma	277
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial	277
Microglial activation and tau propagate jointly across Braak stages	277
How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals	276
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics	269
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals	264
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps	264
A roadmap to increase diversity in genomic studies	259
Heat-related mortality in Europe during the summer of 2022	256
Misinformation: susceptibility, spread, and interventions to immunize the public	253
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)	251
Vaccine development for emerging infectious diseases	251
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom	251
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial	251
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies	249
The landscape of mRNA nanomedicine	248
A guide to immunotherapy for COVID-19	247
The next generation of evidence-based medicine	245
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	244
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy	244
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge	244
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial	244
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial	241
An integrated cell atlas of the lung in health and disease	241
Targeting the gut and tumor microbiota in cancer	241
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade	241
The distribution of cellular turnover in the human body	240
Increased global integration in the brain after psilocybin therapy for depression	240
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial	239
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma	230
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2	230
Reporting guidelines for human microbiome research: the STORMS checklist	230
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial	229
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19	228
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes	225
Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma	224
Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach	223
The Global Burden of Disease Study at 30 years	222
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern	221
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California	219
Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis	219
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial	218
How COVID-19 shaped mental health: from infection to pandemic effects	217
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease	217
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland	215
Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial	214
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma	214
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial	214
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity	212
COVID-19 and resilience of healthcare systems in ten countries	211
The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk	209
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial	208
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1	208
Modeling transmission of SARS-CoV-2 Omicron in China	204
An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy	204
Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI	200
A survey of COVID-19 vaccine acceptance across 23 countries in 2022	200
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer	200
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers	200
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor	199
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer	198
Delivering precision oncology to patients with cancer	195
SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland	193
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial	193
Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease	188
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology	188
Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality	187
Delayed production of neutralizing antibodies correlates with fatal COVID-19	186
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis	186
Redefining critical illness	185
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline	184
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021	184
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis	182
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2	182

Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium	181
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma	180
Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial	180
Performance of plasma phosphorylated tau 181 and 217 in the community	179
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma	179
COVID-19 dynamics after a national immunization program in Israel	177
Large-scale genome-wide association study of coronary artery disease in genetically diverse populations	177
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors	176
A correlate of protection for SARS-CoV-2 vaccines is urgently needed	175
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma	175
The future of early cancer detection	173
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial	173
Priorities for cancer research in low- and middle-income countries: a global perspective	172
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis	170
Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19	169
AI in medicine must be explainable	169
Metabolomic profiles predict individual multidisease outcomes	168
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial	166
Comorbidities, multimorbidity and COVID-19	166
Distinction of lymphoid and myeloid clonal hematopoiesis	165
IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies	165
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial	164
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines	163
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results	163
Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19	163
Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy	162
Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial	161
An algorithmic approach to reducing unexplained pain disparities in underserved populations	161
Wearable sensors enable personalized predictions of clinical laboratory measurements	161
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia	160
Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants	160
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial	160
Postacute sequelae of COVID-19 at 2 years	160
Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease	160
Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19	160
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial	159
Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma	158
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial	155
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring	155
Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases	154
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer	153
Engineered cellular immunotherapies in cancer and beyond	152
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial	152
Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave	151
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER	151
Challenges and opportunities in NASH drug development	150
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial	150
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial	149
Modeling human adaptive immune responses with tonsil organoids	149
An ensemble of neural networks provides expert-level prenatal detection of complex congenital heart disease	146
Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases	146
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)	146
Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals	145
Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis	145
A neuroimaging biomarker for sustained experimental and clinical pain	144
Will ChatGPT transform healthcare?	144
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy	144
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial	142
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing	142
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials	142
Microbiome and metabolome features of the cardiometabolic disease spectrum	141
Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake	141
State-dependent responses to intracranial brain stimulation in a patient with depression	140
Humoral signatures of protective and pathological SARS-CoV-2 infection in children	140
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial	139
Real-world effectiveness of a single dose of mpox vaccine in males	138
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial	138
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy	137
Noninvasive proteomic biomarkers for alcohol-related liver disease	137
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication	136
AlphaFold heralds a data-driven revolution in biology and medicine	134
Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome	133
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials	130
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial	130
The effects of tobacco control policies on global smoking prevalence	130
Integrative microbiomics in bronchiectasis exacerbations	129
Prospective, multi-site study of patient outcomes after implementation of the TREWS machine learning-based early warning system for sepsis	128
Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection	127
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial	127
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial	127
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial	127
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial	126
Transcriptional analysis of cystic fibrosis airways at single-cell resolution reveals altered epithelial cell states and composition	125
A visual–language foundation model for pathology image analysis using medical Twitter	124
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease	124
100 years of insulin: celebrating the past, present and future of diabetes therapy	124
Digital health for aging populations	124
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results	123
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy	123
Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection	122
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort	122
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial	121
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial	120
Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma	119
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma	117